Back

Assessing the alignment of obstructive hypertrophic cardiomyopathy pharmacological treatments with ESC guidelines in Germany

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Hypertrophic obstructive cardiomyopathy (HOCM): clearing the roadblock Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Associate Professor Farbod Sedaghat-Hamedani

University Hospital Heidelberg, Heidelberg (Germany)

8 More presentations in this session

Presentation thumbnail
Epidemiology and prognosis of obstructive and non-obstructive hypertrophic cardiomyopathy in Finland: a nationwide cohort study
Assistant Professor M. Laine (Helsinki, FI)
Abstract Slides Video
Presentation thumbnail
Non-invasive assessment of left ventricular hemodynamic forces in hypertrophic cardiomyopathy
Doctor G. Panichella (Florence, IT)
Abstract Slides Video
Presentation thumbnail
Functional capacity by cardiopulmonary exercise testing is not related to health status in obstructive hypertrophic cardiomyopathy
Doctor L. Bjerregaard (Aarhus N, DK)
Abstract Slides Video
Presentation thumbnail
Hemodynamic effects of right and biventricular pacing during exercise in hypertrophic obstructive cardiomyopathy
Doctor T. Ahmed (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Evaluation of clinical need, effectiveness, and safety of the first myosin inhibitor mavacamten in real world patients
Doctor L. Seuthe (Cologne, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertrophic obstructive cardiomyopathy (HOCM): clearing the roadblock

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Real-world clinical and economic outcomes of nonobstructive hypertrophic cardiomyopathy: a german claims data analysis
thumbnail
Congress Presentation
Clinical burden of obstructive and non-obstructive hypertrophic cardiomyopathy: insights from a nationwide study in France
thumbnail
Congress Presentation
Real-world insights into treatment modalities and emerging myosin inhibitor therapy for hypertrophic obstructive cardiomyopathy: early findings from the German REDUCE-Registry

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources